Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Intocell Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner and is located in a single art unit. The company's active patent prosecution is currently focused within a single administrative unit. This concentration simplifies the management of the portfolio by limiting the number of procedural standards the applicant must follow.
CHANDRAKUMAR, NIZAL S is the busiest examiner for this portfolio, overseeing 1 pending office action. This accounts for the 1 pending office action total for the company. The evaluation of this biotechnology asset is entirely under the purview of this one examiner. Success in the Biotechnology & Pharmaceuticals sector for this application will require a response strategy that addresses the specific technical concerns of this assigned official.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | CHANDRAKUMAR, NIZAL S | 54d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 54d | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntocell Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Intocell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
